NDA 022405 · Genzyme Corp
Caprelsa
Vandetanib · Oral · Kinase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Apr 6, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
110
9 Phase 3, 1 recruiting
FAERS reports
1,815
1,215 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH CAPRELSA can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving CAPRELSA. Do not use CAPRELSA in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to CAPRELSA administration. Monitor electrolytes periodically. Avoid drugs known to prolong the QT interval [see Warnings and Precautions (5.1) ] . WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH See full prescribing information for complete boxed warning. CAPRELSA can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving CAPRELSA. Do not use CAPRELSA in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia...
What it is approved for
From the label in effect Oct 30, 2026.
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 )
Mechanism: In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the N-desmethyl metabolite of the drug, representing 7 to 17.1% of vandetanib exposure, has similar inhibitory activity to the parent compound for VEGF receptors (KDR and Flt-1) and EGFR. In vitro...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 7, 2024 Supplement 22 · Efficacy OrphanLetterLabelMedication Guide
- Oct 12, 2018 Supplement 14 · Efficacy OrphanLabelLetter
- Apr 6, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewSummary ReviewLabel
2 products under this application
- CAPRELSA · VANDETANIB 100MG · TABLET, ORAL · Prescription
- CAPRELSA · VANDETANIB 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vandetanib" as an intervention, any sponsor and status, largest first.
- ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung CancerPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00312377 · 1,690 participants · Start May 2006 · Primary completion Aug 2008
Drug: Docetaxel; Vandetanib · For: Non-small Cell Lung Cancer; Lung Cancer
Sites: Fullerton, California; Los Angeles, California; Northridge, California · 156 sites in all
- Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00364351 · 1,574 participants · Start Aug 2006 · Primary completion Sep 2008
Drug: Vandetanib; Erlotinib · For: Non Small Cell Lung Cancer
Sites: Berkeley, California; Los Angeles, California; Santa Rosa, California · 153 sites in all
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
- ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00404924 · 1,140 participants · Start Nov 2006 · Primary completion Oct 2009
Drug: ZD6474 (vandetanib) · For: Non-Small-Cell Lung Carcinoma
Sites: Tucson, Arizona; Germantown, Tennessee; Bahía Blanca, Argentina · 102 sites in all
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT02117167 · 999 participants · Start Apr 23, 2014 · Primary completion Dec 22, 2018
Drug: AZD2014; AZD4547 and 9 more · For: Non-small Cell Lung Cancer Metastatic
Sites: Avignon, France; Besançon, France; Bobigny, France · 37 sites in all
- Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00418886 · 698 participants · Start Jan 2007 · Primary completion Sep 2008
Drug: Vandetanib; Pemetrexed · For: Non Small Cell Lung Cancer; Lung Cancer
Sites: Casa Grande, Arizona; Chandler, Arizona; Farmington, Connecticut · 110 sites in all
- An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00410761 · 331 participants · Start Nov 23, 2006 · Primary completion Jul 31, 2009
Drug: ZD6474 (Vandetanib) · For: Thyroid Cancer
Sites: Little Rock, Arkansas; San Francisco, California; Aurora, Colorado · 127 sites in all
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerPivotal-lookingActive, not recruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT04211337 · 291 participants · Start Feb 11, 2020 · Primary completion May 22, 2023
Drug: Selpercatinib; Cabozantinib and 1 more · For: Medullary Thyroid Cancer
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 143 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea332
- rash177
- fatigue176
- electrocardiogram qt prolonged142
- hypertension115
- nausea114
- acne98
- disease progression81
- asthenia79
- blood pressure increased79
- dyspnoea77
- headache74
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2008 | 17 |
| 2009 | 21 |
| 2010 | 20 |
| 2011 | 149 |
| 2012 | 247 |
| 2013 | 119 |
| 2014 | 71 |
| 2015 | 78 |
| 2016 | 115 |
| 2017 | 62 |
| 2018 | 85 |
| 2019 | 73 |
| 2020 | 135 |
| 2021 | 150 |
| 2022 | 123 |
| 2023 | 111 |
| 2024 | 99 |
| 2025 | 78 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Caprelsa (Vandetanib)
2024 spending
$3.4M
Beneficiaries
28
214 claims
Per beneficiary
$122,861
$417.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,062,081 |
| 2021 | $7,055,411 |
| 2022 | $3,712,076 |
| 2023 | $3,136,064 |
| 2024 | $3,440,120 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, et al. · N Engl J Med 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, et al. · Lancet Diabetes Endocrinol 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Brose MS, Capdevila J, Elisei R, et al. · Endocr Relat Cancer 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA, Robinson BG, Gagel RF, et al. · J Clin Oncol 2012 · Clinical Trial, Phase III, Multicenter Study
- Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Wirth LJ, Brose MS, Subbiah V, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.